Cladribine May Allow MS Treatment Pause in Older Adults: Study

For individuals with multiple sclerosis (MS) considering stopping disease-modifying therapies (DMTs), a new study offers encouraging findings. Researchers suggest that cladribine tablets may provide a safe “exit strategy” for those aged 50 and older, allowing them to discontinue DMTs with a minimal risk of relapse. The findings, while preliminary, address a growing need for tailored treatment approaches in an aging MS population.

The Challenge of Long-Term DMTs

Multiple sclerosis is a chronic, progressive neurological disease affecting the brain and spinal cord. DMTs have become a cornerstone of MS management, aiming to reduce the frequency and severity of relapses and slow disease progression. However, long-term use of these therapies can present challenges, particularly for older adults who often experience multiple co-existing health conditions and are more susceptible to adverse effects from immunosuppressive treatments.

As a neurologist involved in the study explained, the question of how to best treat aging patients with MS is becoming increasingly relevant. The proportion of individuals in this age group is rising, and there’s a growing recognition that treatment strategies need to evolve to address their unique needs. Many patients and physicians are seeking options to reduce the burden of long-term medication, especially when the disease appears stable.

Cladribine as a Potential “Exit Strategy”

Cladribine tablets work by selectively reducing certain types of immune cells believed to contribute to MS disease activity. Unlike some DMTs that require continuous administration, cladribine is administered in two short courses, one year apart, offering a finite treatment duration. This intermittent dosing schedule and limited course make it an appealing option for patients seeking to transition off continuous therapy.

The recent study, involving 75 patients, compared those under 50 to those over 50 who switched from their existing DMT to cladribine. The results indicated a comparable safety and efficacy profile between the two age groups. While the study population was relatively small, the findings suggest that cladribine may be a viable option for older patients who wish to discontinue DMTs without significantly increasing their risk of relapse.

Real-World Evidence Supports Findings

This study builds upon existing research highlighting the potential benefits of cladribine in older MS patients. A narrative review published in April 2024 emphasized that cladribine tablets could be particularly useful for aging individuals with MS who often have multiple health issues and are more vulnerable to the side effects of ongoing immunosuppression. The review highlighted the need for more tailored treatment strategies for this population.

Further supporting these findings, a real-world study presented at a recent conference showed that cladribine could serve as a “last MS drug” for patients over 50. The study’s author noted that while many patients continue to benefit from DMTs, others may prefer a different approach, especially if their disease is stable. The decision to discontinue DMTs is often a collaborative one between patient and physician, taking into account individual circumstances and preferences.

Understanding the DISCOMS Study and Patient Philosophy

The rationale behind exploring cladribine as an exit strategy is partly rooted in the findings of the “Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis” (DISCOMS) study. This research, along with patient preferences, influences treatment decisions. Some patients express a desire to avoid ongoing medication if they are doing well on their current therapy, adopting a “if it’s not broken, don’t fix it” philosophy.

Long-Term Management and Considerations

Research continues to investigate the long-term effects of cladribine and its impact on immune reconstitution in MS patients. Experts emphasize the importance of careful monitoring and management after year four of treatment. This includes assessing immune cell counts and addressing any potential infections or complications.

The use of cladribine as an exit strategy is not without its considerations. It’s crucial to remember that MS is a highly individual disease, and treatment decisions should be made on a case-by-case basis. Factors such as disease activity, disability level, and overall health status all play a role in determining the most appropriate course of action.

Looking Ahead

The emerging evidence suggests that cladribine tablets may offer a valuable option for older patients with MS who are seeking to transition off DMTs. However, further research is needed to confirm these findings and to better understand the long-term effects of this approach. As the MS community continues to confront the challenges of treating an aging population, tailored treatment strategies like this will become increasingly important.

this information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.